{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:18:49Z","timestamp":1780539529632,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR17550\/MED\/30\/1755\/2016"],"award-info":[{"award-number":["BT\/PR17550\/MED\/30\/1755\/2016"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Age-related macular degeneration (AMD) is a devastating retinal disease that results in irreversible vision loss in the aged population. The complex genetic nature and degree of genetic penetrance require a redefinition of the current therapeutic strategy for AMD. We aimed to investigate the role of modifiers for current anti-VEGF therapy especially for non-responder AMD patients. We recruited 78 wet AMD cases (out of 278 AMD patients)\u00a0with their socio-demographic and treatment regimen. Serum protein levels were estimated by ELISA in AMD patients. Data pertaining to the number of anti-VEGF injections given\u00a0(in 1\u00a0year) along with clinical images (FFA and OCT) of AMD patients were also included. Visual acuity data\u00a0(logMAR) for 46 wet AMD cases out of a total of 78 patients were also retrieved\u00a0to examine\u00a0the response of anti-VEGF injections in wet AMD cases. Lipid metabolizing genes (LIPC and APOE) have been identified as chief biomarkers for anti-VEGF response in AMD patients. Both genotypes\u00a0\u2018CC\u2019 and \u2018GC\u2019\u00a0of LIPC\u00a0have\u00a0found to be associated with a\u00a0number of anti-VEGF injections in AMD patients\u00a0which could influence the\u00a0expression of B3GALTL,HTRA1, IER3, LIPC and SLC16A8\u00a0proteins in patients bearing both genotypes\u00a0as compared to reference genotype.\u00a0Elevated levels of APOE were\u00a0also observed in\u00a0group 2 wet AMD patients as compared to group 1 suggesting the significance of APOE levels in anti-VEGF response.\u00a0The genotype of B3GALTL has also been shown to have a significant association with the number of anti-VEGF injections. Moreover, visual acuity of group 1 (\u2264\u20094 anti-VEGF injections\/year) AMD patients was found significantly improved after 3 doses of anti-VEGF injections and maintained longitudinally as compared to groups 2 and 3. Lipid metabolising genes may impact the outcome of anti-VEGF AMD treatment.<\/jats:p>","DOI":"10.1038\/s41598-021-04269-6","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T11:03:33Z","timestamp":1642071813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modulated anti-VEGF therapy under the influence of lipid metabolizing proteins in Age related macular degeneration: a pilot study"],"prefix":"10.1038","volume":"12","author":[{"given":"Kaushal","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Battu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"4269_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fnagi.2014.00151","volume":"6","author":"K Sharma","year":"2014","unstructured":"Sharma, K., Sharma, N. K. & Anand, A. Why AMD is a disease of ageing and not of development: Mechanisms and insights. Front. Aging Neurosci. 6, 151 (2014).","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"4269_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. 48(2), 134\u2013143 (2016).","journal-title":"Nat. Genet."},{"issue":"6","key":"4269_CR3","doi-asserted-by":"publisher","first-page":"e0248523","DOI":"10.1371\/journal.pone.0248523","volume":"16","author":"K Sharma","year":"2021","unstructured":"Sharma, K., Singh, R., Sharma, S. K. & Anand, A. Sleeping pattern and activities of daily living modulate protein expression in AMD. PLoS ONE 16(6), e0248523 (2021).","journal-title":"PLoS ONE"},{"issue":"20","key":"4269_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897\u20131908 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"4269_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","volume":"26","author":"RM Rich","year":"2006","unstructured":"Rich, R. M. et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26(5), 495\u2013511 (2006).","journal-title":"Retina"},{"issue":"6","key":"4269_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels, S., Rosenfeld, P. J., Puliafito, C. A., Marcus, E. N. & Venkatraman, A. S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112(6), 1035\u20131047 (2005).","journal-title":"Ophthalmology"},{"issue":"4","key":"4269_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/IAE.0000000000002446","volume":"40","author":"RY Hwang","year":"2020","unstructured":"Hwang, R. Y., Santos, D. & Oliver, S. C. N. Rates of exudative recurrence for eyes with inactivated wet age-related macular degeneration on 12-week interval dosing with bevacizumab therapy. Retina 40(4), 679\u2013685 (2020).","journal-title":"Retina"},{"issue":"8","key":"4269_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/jamaophthalmol.2018.2019","volume":"136","author":"L Lor\u00e9s-Motta","year":"2018","unstructured":"Lor\u00e9s-Motta, L. et al. Association of genetic variants with response to anti-vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol. 136(8), 875\u2013884 (2018).","journal-title":"JAMA Ophthalmol."},{"issue":"11","key":"4269_CR9","doi-asserted-by":"publisher","first-page":"e49905","DOI":"10.1371\/journal.pone.0049905","volume":"7","author":"A Anand","year":"2012","unstructured":"Anand, A. et al. Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PLoS ONE 7(11), e49905 (2012).","journal-title":"PLoS ONE"},{"issue":"1","key":"4269_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.gene.2013.03.052","volume":"523","author":"NK Sharma","year":"2013","unstructured":"Sharma, N. K. et al. CC chemokine receptor-3 as new target for age-related macular degeneration. Gene 523(1), 106\u2013111 (2013).","journal-title":"Gene"},{"issue":"4","key":"4269_CR11","doi-asserted-by":"publisher","first-page":"e0193423","DOI":"10.1371\/journal.pone.0193423","volume":"13","author":"NK Sharma","year":"2018","unstructured":"Sharma, N. K., Sharma, K., Singh, R., Sharma, S. K. & Anand, A. CCL2 single nucleotide polymorphism of rs1024611 implicates prominence of inflammatory cascade by univariate modeling in Indian AMD. PLoS ONE 13(4), e0193423 (2018).","journal-title":"PLoS ONE"},{"issue":"4","key":"4269_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5214\/ans.0972.7531.220408","volume":"22","author":"K Sharma","year":"2015","unstructured":"Sharma, K., Sharma, N. K., Singh, R. & Anand, A. Exploring the role of VEGF in Indian Age related macular degeneration. Ann. Neurosci. 22(4), 232\u2013237 (2015).","journal-title":"Ann. Neurosci."},{"issue":"4","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2174\/156720212803530681","volume":"9","author":"NK Sharma","year":"2012","unstructured":"Sharma, N. K. et al. Single nucleotide polymorphism and serum levels of VEGFR2 are associated with age related macular degeneration. Curr. Neurovasc. Res. 9(4), 256\u2013265 (2012).","journal-title":"Curr. Neurovasc. Res."},{"key":"4269_CR14","first-page":"2","volume":"2","author":"P Battu","year":"2021","unstructured":"Battu, P., Sharma, K., Rain, M., Singh, R. & Anand, A. Serum levels of ARMS2, COL8A1, RAD51B, and VEGF and their correlations in age-related macular degeneration. Curr. Neurovasc. Res. 2, 2 (2021).","journal-title":"Curr. Neurovasc. Res."},{"key":"4269_CR15","doi-asserted-by":"publisher","first-page":"365046","DOI":"10.1155\/2013\/365046","volume":"2013","author":"A Anand","year":"2013","unstructured":"Anand, A. et al. Superoxide dismutase1 levels in North Indian population with age-related macular degeneration. Oxid. Med. Cell Longev. 2013, 365046 (2013).","journal-title":"Oxid. Med. Cell Longev."},{"issue":"1\u20132","key":"4269_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-014-2040-4","volume":"393","author":"NK Sharma","year":"2014","unstructured":"Sharma, N. K. et al. Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype?. Mol. Cell Biochem. 393(1\u20132), 1\u20138 (2014).","journal-title":"Mol. Cell Biochem."},{"issue":"1 Pt 2","key":"4269_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygeno.2020.09.044","volume":"113","author":"K Sharma","year":"2021","unstructured":"Sharma, K., Sharma, N. K., Singh, R., Sharma, S. K. & Anand, A. Gene networks determine predisposition to AMD. Genomics 113(1 Pt 2), 514\u2013522 (2021).","journal-title":"Genomics"},{"issue":"4","key":"4269_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/1389202915666140516204512","volume":"15","author":"A Anand","year":"2014","unstructured":"Anand, A., Sharma, K., Chen, W. & Sharma, N. K. Using current data to define new approach in age related macular degeneration: Need to accelerate translational research. Curr. Genom. 15(4), 266\u2013277 (2014).","journal-title":"Curr. Genom."},{"issue":"5","key":"4269_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3928\/23258160-20160419-09","volume":"47","author":"S Cheng","year":"2016","unstructured":"Cheng, S. & Leng, T. Factors associated with poor response to aflibercept after switching from ranibizumab or bevacizumab in neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging Retina. 47(5), 458\u2013465 (2016).","journal-title":"Ophthalmic Surg. Lasers Imaging Retina."},{"issue":"1","key":"4269_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","volume":"2","author":"T Cabral","year":"2018","unstructured":"Cabral, T. et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol. Retina. 2(1), 31\u201337 (2018).","journal-title":"Ophthalmol. Retina."},{"issue":"4","key":"4269_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0041-111801","volume":"233","author":"I Habibi","year":"2016","unstructured":"Habibi, I. et al. Effect of risk alleles in CFH, C3, and VEGFA on the response to intravitreal bevacizumab in tunisian patients with neovascular age-related macular degeneration. Klin Monbl Augenheilkd. 233(4), 465\u2013470 (2016).","journal-title":"Klin Monbl Augenheilkd."},{"issue":"4","key":"4269_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/tjo.tjo_72_19","volume":"9","author":"FJ Rodr\u00edguez","year":"2019","unstructured":"Rodr\u00edguez, F. J. et al. Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population. Taiwan J. Ophthalmol. 9(4), 243\u2013248 (2019).","journal-title":"Taiwan J. Ophthalmol."},{"issue":"8","key":"4269_CR23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/jcb.25837","volume":"118","author":"K Sharma","year":"2017","unstructured":"Sharma, K., Tyagi, R., Singh, R., Sharma, S. K. & Anand, A. Serum Levels of TIMP-3, LIPC, IER3, and SLC16A8 in CFH-Negative AMD cases. J. Cell Biochem. 118(8), 2087\u20132095 (2017).","journal-title":"J. Cell Biochem."},{"key":"4269_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fnagi.2016.00115","volume":"8","author":"A Anand","year":"2016","unstructured":"Anand, A. et al. AMD genetics in India: The missing links. Front. Aging Neurosci. 8, 115 (2016).","journal-title":"Front. Aging Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04269-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:06:40Z","timestamp":1669324000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04269-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}